INTS (Intensity Therapeutics) Additional Paid-In Capital : $70.46 Mil(As of Mar. 2025)

View and export this data going back to 2023. Start your Free Trial

What is Intensity Therapeutics Additional Paid-In Capital?

Intensity Therapeutics's quarterly additional paid-in capital increased from Sep. 2024 ($66.38 Mil) to Dec. 2024 ($69.70 Mil) and increased from Dec. 2024 ($69.70 Mil) to Mar. 2025 ($70.46 Mil).

Intensity Therapeutics's annual additional paid-in capital increased from Dec. 2022 ($23.56 Mil) to Dec. 2023 ($63.68 Mil) and increased from Dec. 2023 ($63.68 Mil) to Dec. 2024 ($69.70 Mil).

Intensity Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Intensity Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intensity Therapeutics Additional Paid-In Capital Chart

Intensity Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

21.67

22.39

23.56

63.68

69.70

Intensity Therapeutics Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Additional Paid-In Capital	Get a 7-Day Free Trial														64.84	65.43	66.38	69.70	70.46

Intensity Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Intensity Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Intensity Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Intensity Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intensity Therapeutics Inc (NAS:INTS) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Enterprise Drive, Suite 430, Shelton, CT, USA, 06484-4779

Website

https://www.intensitytherapeutics.com

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Executives

Emer Leahy	director	1111 LINCOLN ROAD, SUITE 500, MIAMI BEACH FL 33139
Daniel Donovan	director	712 VISTA BLVD #305, WACONIA MN 55387
James M Ahlers	officer: Executive VP of CF	2000 POWELL STREET, SUITE 1640, EMERYVILLE CA 94608
Lewis H Bender	director, 10 percent owner, officer: President and CEO	765 OLD SAW MILL RIVER RD, TARRYTOWN NY 10591
Mark A Goldberg	director	PERCEPTIVE INFORMATICS INC, 200 WEST STREET, WALTHAM MA 02451
John M Wesolowski	officer: Interim CFO	61 WILTON ROAD, 3RD FLOOR, WESTPORT CT 06880